A well-developed coronary collateral circulation provides an alternative source of blood supply in obstructive coronary artery disease. However, the prognostic importance and functional relevance of coronary collaterals is in debate, in particular, with respect to the association of exercise and collateral growth. Therefore, we investigated the impact of high-intensity and moderate-intensity exercise training on the coronary collateral blood flow (collateral flow index) in comparison with usual care. In comparison with the control group, a 4-week protocol of both high-intensity and moderateintensity training in patients with stable coronary artery disease resulted in a significant increase in collateral flow index, physical exercise capacity, peak oxygen uptake, and ischemic threshold. Spearman rank correlation confirmed a significant association between the increase in collateral flow index and ischemic threshold. We noted no differences between high and moderate intensities in regard to the primary and secondary end points at 4 weeks. High-intensity exercise did not invariably result in greater collateral flow index in comparison with moderate-intensity physical exercise. Therefore, the consistent stimulation of collateral channels by exercise may have important clinical benefits for these patients. It can be expected that, by raising of the ischemic threshold during exercise, the residual blood flow at the time of total coronary occlusion will be increased, enabling ischemic cells to survive. The current study provides new insights into the role of regular physical exercise on the coronary collaterals in patients with stable coronary artery disease. Further studies with a larger number of patients are warranted to confirm our results and implement physical activity in secondary prevention recommendations in patients with stable coronary artery disease. See p 1438.
ABO Blood Group and Risk of Thromboembolic and Arterial Disease: A Study of 1.5 Million Blood Donors
ABO blood groups have previously been found to be associated with arterial and venous thrombosis, with consistently increased risks observed among individuals with blood group A, AB, or B compared with those with blood group O. However, the reported risk magnitudes from previous studies have been inconsistent and often come from small studies. In the present study, we used data on 1.1 million healthy blood donors from the binational SCANDAT2 (Scandinavian Donations and Transfusions) database, which contains nationwide data on blood donations and transfusions from Sweden and Denmark, to investigate the relationship between ABO blood group and arterial/venous thrombotic events. Our results confirm that individuals with non-O blood groups are at significantly increased risks of both venous and arterial thromboembolic events, with the highest relative risks observed for venous events. As a result of the high prevalence of the non-O blood groups, as much as 30% to 40% of venous events in this healthy population can be attributed to factors related to these blood groups. Associations persisted also for recurrent and provoked venous thrombosis, but with generally lower relative risk estimates. The proposed underlying mechanisms driving these associations include higher concentrations of factor VIII and von Willebrand factor in individuals with non-O blood groups. Our results indicate that ABO blood group could perhaps be used along with the established risk factors both during the assessment of thromboembolic disease and during decision making for secondary prevention with prophylactic antithrombotic therapy. See p 1449.
Cardiac Stim1 Silencing Impairs Adaptive Hypertrophy and Promotes Heart Failure Through Inactivation of mTORC2/Akt Signaling
Cardiac hypertrophy is a compensatory response to increased mechanical load or to neurohormonal stimulation that reduces wall stress by increasing wall thickness. Although it represents an initial salutary adaptation to stress, chronic hypertrophic remodeling involves maladaptive changes in cardiac function over the long term. Different molecules and signaling circuits have been shown to regulate hypertrophic growth but the upstream events at the level of sarcolemma that initiate the cardiac hypertrophic responses remain largely unknown. Here, we provide evidence that stromal interaction molecule 1, previously reported as a critical regulator of cardiomyocyte growth, activates in response to hypertrophic stimulation to tune Akt kinase activity through a direct regulation of mammalian target of rapamycin (mTOR) complex 2 activity. Growing evidence shows that the mTOR pathway plays a key role in the development of cardiac hypertrophy, and we report a direct interaction between stromal interaction molecule 1 and Rictor, a specific component of mTOR complex 2. This ultimately results in repression of the antihypertrophic molecule GSK-3β, thus promoting cardiac growth. Reciprocally, in the absence of stromal interaction molecule 1, the heart is unable to develop or to sustain preestablished cardiac hypertrophy, which rapidly leads to left ventricular dilation and dysfunction. These mechanistic insights show a critical connection between stromal interaction molecule 1 activation and mTOR complex 2/Akt signaling to support cardiac hypertrophic response to stress and avoid rapid transition to heart failure. See p 1458.
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial
Lower extremity peripheral artery disease is a manifestation of atherosclerosis that is associated with functional decline, and the reduced quality of life is related to increased cardiovascular morbidity and mortality. Currently, several treatment options for peripheral artery disease exist; specifically, standard treatment options have included percutaneous Volume 133 ◼ Number 15 ◼ April 12, 2016
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April 12, 2016 transluminal angioplasty, atherectomy, and bare metal stent placement. Despite the treatments available, endovascular management of symptomatic peripheral artery disease remains challenging and is often burdened by restenosis that results in treatment failure. Resulting repeat treatments after primary failure are associated with increased cost and inconvenience to the patient. New treatment strategies were developed in an effort to reduce restenosis rates; namely, drug-eluting stents (DES), which had clinical success in the treatment of coronary artery disease, were expanded to include treatment of the superficial femoral artery. This multicenter study, with sites in the United States, Japan, and Germany, was initiated to evaluate the safety and durability of treatment with the paclitaxel-coated DES, the Zilver PTX. Patients with symptomatic disease (ie, Rutherford category ≥2 and ≥50% diameter stenosis) of above-the-knee femoropopliteal arteries were randomly assigned to either receive percutaneous transluminal angioplasty or primary DES. In total, 238 patients were randomly assigned to the percutaneous transluminal angioplasty group and 241 patients were randomly assigned to the primary DES group. Subsequently, 120 patients with acute percutaneous transluminal angioplasty failure were further randomly assigned to provisional DES (n=61) or provisional bare metal stent placement (n=59). Comparisons and outcomes were followed through 5 years. The outcomes support the sustained safety and more durable clinical benefit of the DES treatments in comparison with standard care treatment options; namely, the patency benefit is not only sustained, but continues to increase through 5 years. The data also demonstrate the long-term benefit of DES use over bare metal stent placement. Therefore, as one of the largest randomized controlled trials of an endovascular device to treat patients with femoropopliteal artery disease, and the first to provide 5-year follow-up, the Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery (Zilver PTX Randomized Clinical Trial) provides long-term data and insights regarding the durability of endovascular therapies of the femoropopliteal arteries for patients who have claudication or critical limb ischemia. See p 1472.
Selective Stimulation of Cardiac Lymphangiogenesis Reduces Myocardial Edema and Fibrosis Leading to Improved Cardiac Function Following Myocardial Infarction
The pathophysiological role of the lymphatic system has become increasingly recognized over the past decade, extending from control over interstitial fluid balance to regulation of inflammation, but also impacting tumor metastasis in patients who have cancer. However, the lymphatic network of the heart has been largely neglected. Although therapeutic lymphangiogenesis is currently being proposed as a novel treatment against edema or chronic inflammation in peripheral organs, it has remained unknown whether lymphangiogenesis in the heart may impact cardiac function, notably in cardiovascular diseases such as myocardial infarction and chronic heart failure, characterized by myocardial edema and inflammation. In this study, we show that myocardial infarction induces severe cardiac lymphatic network remodeling and lymphatic transport dysfunction, which together with insufficient lymphangiogenesis contribute to the initiation of chronic myocardial edema and inflammation. Furthermore, we assessed the impact of selective targeted lymphangiogenic therapy in the heart. Promisingly, we demonstrate for the first time that cardiac therapeutic lymphangiogenesis is beneficial post-myocardial infarction because it leads to expedited lymphatic clearance of both excess tissue fluids and infiltrating macrophages. As a result, cardiac fibrosis, remodeling, and dysfunction are reduced. Our findings provide new mechanistic insight into the pathophysiology of cardiac remodeling and dysfunction, and open up novel therapeutic approaches to treat cardiovascular diseases including, but not limited to, myocardial infarction and chronic heart failure. Notably, our data may bring renewed interest in vascular endothelial growth factor C therapy for ischemic heart disease, because they provide a new rationale for the clinical trials that were already performed with this angiogenic/lymphangiogenic growth factor 15 years ago. See p 1484.
